Taking the Long View on Rare Disease Drug Pricing - Rob Shaffer

May 07, 2020

Rob Shaffer responds to A. Gordon Smith’s article, “The Cost of Drugs for Rare Diseases Is Threatening the U.S. Health Care System” (Harvard Business Review).

Think of a newly approved drug as you would buying a new home. With the new home comes a mortgage, taxes, insurance, and upkeep; the mortgage is often the most significant of the three, at least upfront. After the 15- or 30-year payment term, you own your house, and just have to pay taxes, insurance, and upkeep, a far less expensive monthly total. Drugs are similar: under patent protection the innovative company can charge a premium to recoup development costs and turn a profit to encourage further investment in the company. After patent expiration, cheap generics compete and drive down the price of the drug, similar to paying off your house and only having to spend on taxes, insurance, and upkeep.

Profits That Shouldn't Hurt - Marion Paolini

May 07, 2020

Marion Paolini responds to Abbey Meller and Hauwa Ahmed’s article, “How Big Pharma Reaps Profits While Hurting Everyday Americans” (American Progress).

In a very recent past life, I was working as a researcher in academia. When I read an article like “How Big Pharma Reaps Profits While Hurting Everyday Americans” by Abbey Meller and Hauwa Ahmed, I find it misleading to read a claim like “Pharmaceutical companies receive substantial U.S. government assistance in the form of publicly funded basic research.” In the lab I was working for, which was part of an academic institution, private contributions, i.e. the pharmaceutical industry, foundations and individual donors, were actually our largest financial contributors, funding over 60 percent of research. The government (taxpayers) contributed to only about a third of the costs.

What are Drugs Worth? - Ben Pope

May 07, 2020

Ben Pope responds to Eric Bender’s article, “Cost of Cancer Drugs: Something Has to Give” (Managed Care Magazine).

I am often puzzled by the enormous sale prices of modern art, partly because I prefer baroque, but also because I am cheap and not in a position to buy much of anything. To me, six inches of duct tape and a banana are worth a few cents, but to certain modern art patrons, the combination was worth more than two years of income for most Americans. Despite my lack of appreciation, the monetary value of this artwork, as with all exchanged goods and services, was determined by the negotiated price someone was willing to pay.

Two Big Drug Flops Show How Healthcare Economics Are Broken by Skewed Incentives - Alex Wang

May 07, 2020

Alex Wang responds to Riley Griffin’s article, “Two Big Drug Flops Show How Health-Care Economics Have Changed” (Bloomberg Businessweek).

Heart disease is the most fatal and prevalent disorder in the United States, costing over 600,000 lives and over $200 billion every year. A critical risk factor for developing heart disease is having high cholesterol, a common condition estimated to affect over 1 in 10 adults or around 60 million Americans. Over the past few decades, millions of people with high cholesterol have been successfully treated with a class of drugs called statins. Statin medications, which slow down cholesterol synthesis, are now a ubiquitous, safe, and cheap class of generic medicines that have kept many alive and out of hospitals. There remains a significant population, however, for whom statins are not as effective, and there have been few alternatives—until recently. In 2015, Sanofi and Amgen launched the first of a new class of cholesterol-lowering drugs called PCSK9 inhibitors. PCSK9 inhibition is an elegant and highly effective way of lowering LDL-cholesterol by turbocharging the body’s own cholesterol elimination system.

Bridging the Divide Between Patients and Drug Developers - Mark Charbonneau

May 07, 2020

Mark Charbonneau responds to Abbey Meller and Hauwa Ahmed’s article, “How Big Pharma Reaps Profits While Hurting Everyday Americans” (American Progress).

For the past several years, I’ve recognized a divide between my professional and personal lives. Professionally, I work as a scientist for a biotechnology company that develops new therapies for patients with rare metabolic diseases, like phenylketonuria (PKU). People with PKU must adhere to extremely low-protein diets to prevent permanent intellectual disability, and these patients desperately need more effective treatments with fewer side effects. I’ve observed firsthand how challenging, expensive, and time-consuming it is for teams of highly trained and creative professionals to develop a new drug.

Taking the Long View on Rare Disease Drug Pricing - Rob Shaffer

Rob Shaffer responds to A. Gordon Smith’s article, “The Cost of Drugs for Rare Diseases Is Threatening the U.S. Health Care System” (Harvard Business Review).

Profits That Shouldn't Hurt - Marion Paolini

Marion Paolini responds to Abbey Meller and Hauwa Ahmed’s article, “How Big Pharma Reaps Profits While Hurting Everyday Americans” (American Progress).

What are Drugs Worth? - Ben Pope

Ben Pope responds to Eric Bender’s article, “Cost of Cancer Drugs: Something Has to Give” (Managed Care Magazine).

Two Big Drug Flops Show How Healthcare Economics Are Broken by Skewed Incentives - Alex Wang

Alex Wang responds to Riley Griffin’s article, “Two Big Drug Flops Show How Health-Care Economics Have Changed” (Bloomberg Businessweek).

Bridging the Divide Between Patients and Drug Developers - Mark Charbonneau

Mark Charbonneau responds to Abbey Meller and Hauwa Ahmed’s article, “How Big Pharma Reaps Profits While Hurting Everyday Americans” (American Progress).

Blog

The Great American Drug Deal’s blog features personal responses to popular articles that criticize the drug industry, written by scientists, students, and those who work in the biopharmaceutical industry.

Featured Posts